MGX (Metagenomi) Ending Cash Position : $32.63 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Metagenomi Ending Cash Position?

Metagenomi's Ending Cash Position for the quarter that ended in Dec. 2024 was $32.63 Mil.

Metagenomi's quarterly Ending Cash Position declined from Jun. 2024 ($66.43 Mil) to Sep. 2024 ($30.37 Mil) but then increased from Sep. 2024 ($30.37 Mil) to Dec. 2024 ($32.63 Mil).

Metagenomi's annual Ending Cash Position declined from Dec. 2022 ($190.51 Mil) to Dec. 2023 ($145.85 Mil) and declined from Dec. 2023 ($145.85 Mil) to Dec. 2024 ($32.63 Mil).

Metagenomi Ending Cash Position Historical Data

The historical data trend for Metagenomi's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Metagenomi Ending Cash Position Chart

Metagenomi Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

43.40

190.51

145.85

32.63

Metagenomi Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Ending Cash Position	Get a 7-Day Free Trial						145.85	107.81	66.43	30.37	32.63

Metagenomi Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Metagenomi's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	145.851	+	-113.217
	=	32.63

Metagenomi's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	30.365	+	2.269
	=	32.63

Metagenomi Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Metagenomi's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Metagenomi Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Metagenomi Inc (NAS:MGX) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

5959 Horton Street, 7th Floor, Emeryville, CA, USA, 94608

Website

https://metagenomi.co

Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.